The Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves

[en] The in vivo ability of the specific PAF-antagonist WEB 2086, a thienotriazolodiazepine, to inhibit platelet-activating factor (PAF) in cattle was investigated by in vitro determination of platelet aggregation curves. WEB 2086 was infused intravenously into a group of 5 healthy male Friesian calves in a dose of 3 mg/kg over 1 min. The resultant inhibition peaked between 30 min and 1 h after administration of WEB 2086. The inhibition was significantly reduced after 3 h and became non-significant after 6 h, but maximal pre-treatment aggregation had not been restored by 24 h after the injection of WEB 2086. These results confirm previous results obtained in vitro and suggest that WEB 2086 is a potent antagonist of PAF activity in calves. They also suggest that further clinical studies with WEB 2086 in cattle are desirable.

Disciplines :

Veterinary medicine & animal health
Anatomy (cytology, histology, embryology...) & physiology

Author, co-author :

Bastos da Silva, Miriam; Université de Liège - ULiège > Faculty of Veterinary Medicine > Laboratory of Functional Investigation

Gustin, Pascal ; Université de Liège - ULiège > Faculty of Veterinary Medicine > Laboratory of Pharmacology and Toxicology

Herion, Francine ; Centre Hospitalier Universitaire de Liège - CHU > Thrombosis Homestasis Unit

Raskinet, Renée ; Centre Hospitalier Universitaire de Liège - CHU > Thrombosis Homestasis Unit

David, Jean-Louis ; Centre Hospitalier Universitaire de Liège - CHU > Thrombosis Homestasis Unit

Gougnard, Thierry; Centre Hospitalier Universitaire de Liège - CHU > Laboratory of Clinical Toxicology

Plomteux, Guy ; Centre Hospitalier Universitaire de Liège - CHU > Laboratory of clinical toxicology

Desmecht, Daniel ; Université de Liège - ULiège > Faculty of Veterinary Medicine > Laboratory of Functional Investigation

Lekeux, Pierre ; Université de Liège - ULiège > Faculty of Veterinary Medicine > Laboratory of Functional Investigation

Language :

English

Title :

The Effect of Intravenous Administration of Web 2086 on Paf-Induced Platelet Aggregation in Healthy Friesian Calves

Publication date :

1997

Journal title :

Veterinary Research Communications

ISSN :

0165-7380

Publisher :

Kluwer Academic Publishers, Dordrecht, Netherlands

Volume :

Issue :

Pages :

521-531

Peer reviewed :

Peer Reviewed verified by ORBi

Funders :

CNPq - Conselho Nacional de Desenvolvimento Científico e Tecnológico

Funding text :

Bastos is a recipent of a grant from CNPq and FCAP Belém-Parà Brazil

Available on ORBi :

since 20 February 2009

Statistics

Number of views

122 (7 by ULiège)

Number of downloads

2 (1 by ULiège)

More statistics

Scopus citations^®

Scopus citations^®
without self-citations

OpenCitations

OpenAlex citations

Bibliography

Adamus, W.S., Heuer, H., Meade, C.J., Frey, G. and Brecht, H.M., 1988a. Inhibitory effect of oral WEB 2086, a novel selective PAF-acether antagonist, on ex-vivo platelet aggregation. European Journal of Clinical Pharmacology, 35, 237-240
Adamus, W.S., Heuer, H., Meade, C.J., Kempe, E.R. and Brecht, H.M., 1988b. Effect of intravenous or inhalative WEB 2086 on ex-vivo platelet activating factor induced platelet aggregation in man. Prostaglandins, 35, 797
Adamus, W.S., Heuer, H., Meade, C.J., Brecht, H.M., 1989. Safety, tolerability, and pharmacologic activity of multiple doses of the new platelet activating factor antagonist WEB 2086 in human subjects. Clinical Pharmacology and Therapeutics, 45 270-276
Barnes, P.J., 1991. Platelet activating factor and asthma. Annals of the New York Academy of Sciences, 629, 193-203
Bastos da Silva, M., Herion, F., David, J.-L., Gustin, P. and Lekeux, P., 1996. Inhibition of PAF-induced platelet aggregation by WEB 2086, an antagonist to the receptor for platelet-activating factor, in bovine. Journal of Veterinary Medicine A, 43, 399-413
Benveniste, J., Tence, M., Varenne, P., Bidault, J., Boullet, C. and Polonsky, J., 1979. Semi-synthèse et structure proposée du facteur activant des plaquettes (PAF): PAF-acéther, un alkyl éther analogue de la lysophosphatidylcholine. Compte-Rendu de l'Academie des Sciences, 289, 1037-1040
Blank, M.L., Snyder, F., Byers, W.L., Brooks, B. and Muirhead, E.E., 1979. Antihypertensive activity of an alkyl ether analog of phosphatidylcholine. Biochemical and Biophysical Research Communications, 90, 523-534
Born, G.V.R. and Cross, M.J., 1963. The aggregation of blood platelets. Journal of Physiology (London), 168, 178-195
Brambilla, A., Ghiorzi, A. and Giachetti, A., 1987. WEB 2086, a potent PAF antagonist, exerts protective effect toward PAF-induced gastric damage. Pharmacological Research Communications, 19, 147-151
Braquet, P., Touqui, L., Shen, T.Y. and Vargaftig, B.B., 1987. Perspectives in platelet-activating factor research. Pharmacological Reviews, 39, 97-145
Brecht, H.M., Adamus, W.S., Heuer, H.O., Birke, F.W. and Kempe, E.R., 1991. Pharmacodynamics, pharmacokinetics and safety profile of the new platelet-activating factor antagonist apafant in man. Drug Research, 41, 51-59
Bowers, L.D., 1989. Liquid chromatography. In: L.A. Kaplan and A.J. Pesce (eds), Clinical Chemistry, 2nd edn, (CV. Mosby Co., Baltimore, Philadelphia), 94-108
Casals-Stenzel, J., Muacevic, G. and Weber, K.H., 1987. Pharmacological actions of WEB 2086, a new specific antagonist of platelet activating factor. Journal of Pharmacology and Experimental Therapeutics, 241, 974-981
David, J.-L., Monfort, F., Herion, F. and Raskinet, R., 1979. Compared effects of three dose-levels of ticlopodine on platelet function in normal subjects. Thrombosis Research, 14, 35-49
Demopoulos, C.A., Pinckard, R.N. and Hanahan, D.J., 1979. Platelet activating factor: evidence for 1-O-alkyl-2-acetyl-sn-glyceryl-3-phosphorylcholine as the active component (a new class of lipid chemical mediators). Journal of Biological Chemistry, 254, 9355-9358
Foster, A.P., Lees, P., Andrews, M.J. and Cunningham, F.M., 1992. Effects of WEB 2086, an antagonist to the receptor for platelet-activating factor (PAF), on PAF-induced responses in the horse. Equine Veterinary Journal, 24, 203-207
Godfroid, J.J., Heymans, F., Michel, E., Redevilh, C., Steiner, E. and Benveniste, J., 1980. Platelet activating factor (PAF-acether): total synthesis of 1-O-octadecyl-2-O-acetyl-sn-glycero-3-phosphoryl-choline. FEBS Lett., 116, 161-164
Henson, P.M. and Pinckard, R.N., 1976. Platelet-activating factor (PAF) as a mediator in IgE anaphylaxis. Federation Proceedings, 35, 516
Heuer, H., 1989. Hetrazepinoic antagonists of platelet activating factor. Drugs Design and Delivery, 5, 33-47
Heuer, H., Birke, F.W, Casals-Stenzel, J. and Weber, K.H., 1988. Inhibition of the binding and aggregation to PAF in-vitro in comparison with PAF-antagonists. Prostaglandins, 35 838
Hugues, R.J. and Osselton, D., 1989. Comparison of methods for the analysis of tricylcic antidepressants in small whole blood samples. Journal of Analytical Toxicology, 13, 77-83
Koltai, M., Hosford, D., Guinot, P., Esanu, A. and Braquet, P., 1991. Platelet activating factor (PAF). A review of its effects, antagonists and possible future clinical implications (Part I). Drugs, 42, 9-29
Koltia, M., Hosford, D. and Braquet, P., 1993. PAF-induced amplification of mediator release in septic shock: prevention or downregulation by PAF antagonists (review). Journal of Lipid Mediators, 6, 183-198
Kornecki, E., Ehrlich, Y.H. and Lenox, R.H., 1984. Platelet-activating factor-induced aggregation of human platelets specifically inhibited by triazolobenzodiazepines. Science, 226, 1454-1456
Lekeux, P., Gustin, P., Desmecht, D. and Linden, A., 1991. Thérapeutique des pathologies respiratoires aiguës des bovins. Annales de Médecine Vétérinaire, 135, 175-184
Maxwell, V.-B., 1993. Airway hyperresponsiveness. Compendium on Continuing Education Practice Veterinary, 15, 1379-1387
Pickering, M.V., 1991. Diode array: new dimensions in detection for high performance liquid chromatography. LC-GC International, 4, 20-25
Pinckard, R.N., McManus, L.M., Halonen, M. and Hanahan, D.J., 1982. Biological activities of acetyl glyceryl ether phosphorycholine in experimental animals and man. In: R. McCom (ed.), Role of Chemical Mediators in the Pathophysiology of Acute Illness and Injury, 3rd edn, (Raven Press, New York), 248-350
Spence, D.P.S., Johnston, S.L., Calverley, P.M.A., Dhillon, P., Higgins, C., Ramhamadany, E., Turner, S., Winning, A., Winter, J. and Holgate, S.T., 1994. The effect of the orally active platelet-activating factor antagonists WEB 2086 in the treatment of asthma. American Journal of Respiratory and Critical Care Medicine, 149, 1142-1148
Suquet, C.M. and Leid, R.W., 1983. Aggregation of equine platelet by PAF (platelet-activating factor). Inflammation, 7, 197-203
Tracqui, A., Kintz, P. and Mangin, P., 1992. High-performance liquid chromatography with photodiode array detection. A new tool in the forensic toxicologic laboratory. Journal de Médecine Légale Droit Médical, 35, 37-40
Vargaftig, B.B., Chignard, M. and Benveniste, J., 1981. Present concepts on the mechanisms of platelet aggregation. Biochemical Pharmacology, 30, 263-271
Vieira, S., 1985. Introdução a Bioestatística, 3rd edn, (Editora Campus, Rio de Janeiro), 223-245
Weber, K. and Heuer, H.O., 1989. Hetrazepines as antagonists of platelet activating factor. Medicinal Research Reviews, 9, 181-218